• background image

  • CSO Expert in Asia

    Founded in 2013 Grandhall Group (GHG) was one of the first contract sales organizations (CSOs) in Asia. GHG is reshaping the way pharmaceutical, Chemicals(APIs), medical device, and diagnostics companies reach and engage customers, commercialize products, and manage their portfolios.

     

    GHG is a leading healthcare commercialization company providing superior insight-driven, integrated multi-channel message delivery for established and emerging healthcare companies.

     

    GHG is dedicated to:

    • Providing outsourced sales and marketing expertise.
    • Creating innovative digital and multi-channel promotional solutions. 
    • Enhancing engagement with health care practitioners.
    • Optimizing clients’ commercial investments.
    • Providing clients with strategic flexibility.
    • Delivering full product commercialization services. 

    GHG helps manufacturers become more competitive in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions. We bring expertise in sales, organizational design, M&A and other disciplines that determine which companies achieve and maintain industry leadership.

  • Explore with GHG

    Understand the business environment in Asia.

    Pharmaceuticals

    Medical Device

    Chemicals

    Diagnostics

  • Perspective

     

    Over the last 25 years, the global pharmaceutical industry has made revolutionary contributions to clinical care. The industry now faces the challenges of unpredictable product pipelines, increasingly competitive markets, and uncertain policy and regulatory environments. Despite ongoing medical need related to many diverse diseases, pharmaceutical companies—much like medical technology companies—can no longer depend on their innovation engines and pricing power to achieve profitable growth.

     

    The net result of ongoing cost pressures and a precipitous decline in R&D productivity will be an unprecedented decline in the share of the overall healthcare profit pool captured by the largest research-based pharmaceutical companies, while lower-margin sectors, like generic manufacturers, will increase their share. The critical question for these companies is how to evolve their business model in order to thrive in a world of shifting profit pools by focusing on outcomes rather than by simply generating more inputs—more products, more procedures and ultimately more cost to the payers.

    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More